Maintenance hamatocrit levels and mortality in hemodialysis patients with renal anemia receiving recombinant human erythropoietin(rHuEPO) treatment(rHuEPO survey).

Yoshihei Hirasawa; Masashi Suzuki; Noritomo Itami; Seiji Ohira; Tsuguo Mizuno; Kentaro Mera; Yoshiharu Haga; Hironobu Kawai; Keiichi Mashimo; Isahiro Obara; Norio Kurosawa; Yasushi Nakamoto; Kazuo Numazawa; Mitsuyoshi Furuhashi; Yukitaka Maruyama; Ryuji Miki; Shigefumi Koike; Hachiro Seno; Hirohisa Kawahara; Hiroyuki Kobayashi; Toshihiko Ono; Senji Okuno; Masao Kim; Ryoichi Miyazaki; Yasushi Saika; Yoshihiro Motomiya; Kazuhi Taniai; Koji Usui; Kenichiro Shigemoto; Takashi Mizuguchi; Shu Kawashima; Kenji Yuasa; Kazumichi Ohta; Takashi Sato; Kenichi Fukunari; Yuzo Kimura; Hisashi Takahashi; Kougi Yuu

Journal ArticleOPEN ACCESS

Maintenance hamatocrit levels and mortality in hemodialysis patients with renal anemia receiving recombinant human erythropoietin(rHuEPO) treatment(rHuEPO survey).

Hirasawa Y
Suzuki M
Itami N
et al.

Nihon Toseki Igakkai Zasshi (2003) 36(7) 1265-1272

DOI: 10.4009/jsdt.36.1265

N/ACitations

2Readers

Abstract

遺伝子組換えヒトエリスロポエチン製剤(rHuEPO)を6ヵ月以上継続投与している,慢性維持血液透析患者2654例を対象に,維持Ht値と生命予後との関係をretrospectiveに調査,検討した.1年及び3年死亡リスクは共にHt値30%以上33%未満の群で有意に低値で,生命予後の観点からみた血液透析患者のrHuEPO治療における至適維持目標Ht値はこの範囲にあると考えられたが,1年死亡リスクは,例数が少ないもののHt値33%以上の群についても低値であった

Cite

CITATION STYLE

APA

Hirasawa, Y., Suzuki, M., Itami, N., Ohira, S., Mizuno, T., Mera, K., … Yuu, K. (2003). Maintenance hamatocrit levels and mortality in hemodialysis patients with renal anemia receiving recombinant human erythropoietin(rHuEPO) treatment(rHuEPO survey). Nihon Toseki Igakkai Zasshi, 36(7), 1265–1272. https://doi.org/10.4009/jsdt.36.1265

Maintenance hamatocrit levels and mortality in hemodialysis patients with renal anemia receiving recombinant human erythropoietin(rHuEPO) treatment(rHuEPO survey).

Abstract

Cite

Register to see more suggestions